AFA
ABMD

Abacus FCF Advisors’s Abiomed Inc ABMD Stock Holding History

Abacus FCF Advisors’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,803
Closed -$928K – 188
2022
Q1 		$928K Buy
+2,803
New +$863K 0.31% 126

Other funds holding ABMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
Winslow Capital Management
Winslow Capital Management Minneapolis, Minnesota $25.6B AUM 33.75% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Abacus FCF Advisors's ABMD Position: Q2 2022 in Review

Abacus FCF Advisors sold out of Abiomed Inc (ABMD) in Q2 2022, closing a stake of 2,803 shares — an estimated $928K sold.

Abacus FCF Advisors first reported a position in ABMD in Q1 2022 and held it in 1 quarter. The position peaked at $928K in Q1 2022. 496 funds tracked by Wall St. Rank hold ABMD as of Q2 2022.

  • Abacus FCF Advisors reported no remaining Abiomed Inc position as of Q2 2022 after selling out during the quarter.
  • Abacus FCF Advisors sold 2,803 Abiomed Inc shares in Q2 2022, an estimated $928K.
  • Abacus FCF Advisors first reported a position in Abiomed Inc in Q1 2022 and held it in 1 quarter.
  • Abacus FCF Advisors's Abiomed Inc position peaked at $928K in Q1 2022.
  • 496 funds tracked by Wall St. Rank held Abiomed Inc as of Q2 2022.

Based on Abacus FCF Advisors's 13F filing for Q2 2022, filed 20 Jul 2022.